SEHK:512Pharmaceuticals
Did TLX591-CDx NDA Acceptance and Nuclear Push Just Reframe Grand Pharmaceutical Group's (SEHK:512) Oncology Story?
Grand Pharmaceutical Group recently reported that China’s NMPA accepted its New Drug Application for TLX591-CDx (Illuccix®, gallium Ga 68 PSMA-11) for prostate cancer diagnosis, following positive Phase III data showing a 94.8% positive predictive value in Chinese patients with biochemically recurrent disease.
Alongside this, the company outlined a broad push in nuclear medicine, with multiple Y-90 liver cancer indications cleared in the US and Europe and several radiopharmaceuticals...